Cornerstone Advisors LLC Buys New Shares in Elevance Health, Inc. $ELV

Posted by Stanley Muller on Aug 18th, 2026

Cornerstone Advisors LLC bought a new position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 34,721 shares of the company’s stock, valued at approximately $13,428,000.

A number of other hedge funds have also recently bought and sold shares of ELV. M&T Bank Corp raised its position in Elevance Health by 160.4% during the fourth quarter. M&T Bank Corp now owns 50,486 shares of the company’s stock worth $17,698,000 after acquiring an additional 31,101 shares in the last quarter. Solidarity Wealth LLC bought a new position in shares of Elevance Health in the 4th quarter valued at about $1,433,000. Manning & Napier Advisors LLC increased its stake in shares of Elevance Health by 1,423.1% during the 4th quarter. Manning & Napier Advisors LLC now owns 368,426 shares of the company’s stock worth $129,152,000 after purchasing an additional 344,237 shares during the last quarter. Stoneridge Investment Partners LLC acquired a new position in shares of Elevance Health during the 2nd quarter worth about $970,000. Finally, Mawer Investment Management Ltd. raised its holdings in shares of Elevance Health by 10.9% in the 4th quarter. Mawer Investment Management Ltd. now owns 207,095 shares of the company’s stock valued at $72,597,000 after purchasing an additional 20,438 shares during the period. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Stock Down 2.4%

Shares of ELV opened at $390.69 on Tuesday. Elevance Health, Inc. has a 52 week low of $274.84 and a 52 week high of $436.24. The firm has a market cap of $84.73 billion, a P/E ratio of 17.36, a price-to-earnings-growth ratio of 2.30 and a beta of 0.68. The firm’s 50-day simple moving average is $395.48 and its 200 day simple moving average is $358.49. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.52 and a current ratio of 1.52.

Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.21 by $1.24. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The firm had revenue of $49.83 billion during the quarter, compared to the consensus estimate of $48.88 billion. During the same period last year, the business posted $8.84 earnings per share. The business’s revenue for the quarter was up .8% compared to the same quarter last year. On average, analysts forecast that Elevance Health, Inc. will post 27.07 earnings per share for the current year.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Thursday, September 10th will be paid a $1.72 dividend. The ex-dividend date is Thursday, September 10th. This represents a $6.88 annualized dividend and a yield of 1.8%. Elevance Health’s payout ratio is 30.58%.

Insider Buying and Selling

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director owned 10,734 shares in the company, valued at $4,312,599.18. This trade represents a 1.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.34% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ELV has been the subject of a number of research analyst reports. Morgan Stanley lifted their price target on Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a report on Thursday, June 4th. Royal Bank Of Canada dropped their price objective on Elevance Health from $439.00 to $424.00 and set a “sector perform” rating on the stock in a research note on Thursday, July 16th. TD Cowen raised their price objective on Elevance Health from $400.00 to $465.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Raymond James Financial set a $450.00 target price on Elevance Health in a research note on Tuesday, July 7th. Finally, Sanford C. Bernstein set a $488.00 target price on Elevance Health in a report on Thursday, July 16th. Fifteen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $440.90.

Get Our Latest Report on Elevance Health

Elevance Health Company Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.